Dear readers of ADxS.org, please forgive the disruption.

ADxS.org needs about $36850 in 2023. In 2022 we received donations from third parties of about $ 13870. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2023 would be over after a few days. This donation request is displayed 18,000 times a week, but only 40 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$9319 of $36850 - as of 2023-06-01
25%
Header Image
Centanafadine for ADHD

Sitemap

Centanafadine for ADHD

Centanafadine is a

  • Norepinephrine reuptake inhibitor
  • Dopamine reuptake inhibitor
  • Serotonin reuptake inhibitors.

Two randomized, double-blind, placebo-controlled, parallel-group, phase 3 studies were conducted in adults with ADHD with 200 mg/d or 400 mg/d of centanafadine sustained-release tablets.1
At day 42, both studies showed improvements in AISRS total score versus placebo with effect sizes of -0.28 for 200 mg/d and -0.24 for 400 mg/d in study 1 and -0.37 for 200 mg/d and -0.40 for 400 mg/d in study 2.

Centanafadine was well tolerated, and the overall rate of adverse events was low but dose-dependent.

Centanafadine is currently being evaluated in multiple clinical trials for its efficacy and safety in children and adolescents with ADHD (NCT05279313, NCT05428033, NCT05257265).2